Sanofi Global Health launches non-profit brand Impact® to

0

Sanofi Global Health launchare Nonprofit Impact® mark for 30 medications in low income countries

  • Medicines, including insulin, will be available in 40 low-income countries
  • Creation of an investment fund to help create sustainable health systems
  • The announcements come as global health players gather in Paris

Pjumpscares Julily 42022 Sanofi Global Health announces the launch of Impact®, a New Mark of standard of care medicines produced by Sanofi dedicated for non-profit distribution to populations at risk in the of the world poorest countries.

The Impact® Markwhich includes among others insulin, glibenclamide and oxaliplatin, will allow the safety distribution of 30 Sanofi medications in 40 lowerincome countries. Considered essential by the World Health Organization, the drugs cover a wide range of therapeutic areas, including diabetes, cardiovascular disease, tuberculosis, malaria and cancer.

The launch of the Impact® brand is one of the steps taken since the creation last year of Sanofi Global Healtha not-for-profit unit within the company aimed at increasing access to health care through the distribution of medicines, as well as building and strengthening local health systems in countries with GDP per per capita is among the lowest. Sanofi Global Health Iit’s the first and only global initiative give access to such a wide drug portfolio in so many countries and across multiple therapeutic areas while funding local support programs and strengthening local inclusive businesses.

Paul Hudson
Chairman and CEO, Sanofi
“At Sanofi, we believe we have a responsibility to make a difference to the health of those who need it most, and we we know have the ability and ambition to bring about lasting change. With critical medicationstirelessly conduct and impactful partnershipswe can take our innovation beyond the laboratory and use it for strengthening health systems and access to drugs for the most vulnerable patient communities. Sanofi Global Health aims to improve the lives of millions of people who can no longer get the help they need. Sanofi renewed goal is to chase the miracles of science to improve people’s lives. And our quest to make life better for all must include helping to provide better access to quality care and medicines for underserved populations.”

The company also announces the creation of a Impact funds It’s okay support startups and other innovators who can provide scalable solutions for sustainable healthcare in underserved regions. Providing inclusive businesses financing and technical assistancethe fund will complement the GHU’s mission to benefit global, regional and local investments for Support the coaching of health professionals and assistanceing communities Race sustainable care systems. These announcements come as Sanofi brings together key players in global health to discuss how to deliver effective and integrated end-to-end health programs in the communities in which they serve, in order to reach, treat and to better manage the health of patients in an efficient and sustainable way.

Jon Fairst
Head, Global Health Unit, Sanofi
The launch of the Impact® brand and our Impact Fund are our final steps to make our medicines available and help bring quality, sustainable healthcare to people in the world’s poorest countries. But we know we can’t do it alone, so we’re building partnerships globally, regional and local levels that will help improve and build health systems to achieve our goal of a healthier and more resilient world.

Sanofi Global Health is one of three elements of Sanofi’s multi-level approach to social impact, which includes Foundations – the Sanofi collective dedicated to philanthropy and one VScompany Ssocial Rresponsibility strategy integrated in orr Commercial activities:

  • Foundations focuses on efforts to fight childhood cancer, increase the health resilience of populations most affected by climate change, and provide product donations to address humanitarian crises. Continuing the company’s 30-year legacy, Sanofi is also committed to make a donationing 100,000 bottles each year for free to support patients with five different lysosomal storage disorders (LSDs), a group of rare genetic diseases caused by enzyme deficiencies.
  • Our company-wide CSR strategy revolves around four pillars: affordable to access; innovation for vulnerable communities; planet care, in the workplace and beyond; in addition at the responsible company. It is built around flagship initiatives spread across the entire value chain of the company, from R&D to manufacturing to commercial operations, considering that each part of the organization has a role to play and a contribution to to bring.

About Sanofi
We are an innovative global healthcare company driven by one purpose: we pursue the miracles of science to improve people’s lives. Our team, present in over 100 countries, is dedicated to transforming the practice of medicine by striving to turn the impossible into the possible. We provide potentially game-changing treatment options and life-saving vaccine protection to millions of people around the world, while placing sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations
Nicholas Obrist | + 33 6 77 21 27 55 | [email protected]
Evan Berland | + 1 215 432 0234 | [email protected]

Sanofi Investor Relations
Eva Schäfer-Jansen | + 33 7 86 80 56 39 | [email protected]
Arnaud Delépine | + 33 6 73 69 36 93 | [email protected]
Corentine Driancourt | + 33 6 40 56 92 21 | [email protected]
Felix Lauscher | + 1 908 612 7239 | [email protected]
Priya Nanduri | +1 617 764 6418 | [email protected]
Nathalie Pham | + 33 7 85 93 30 17 | [email protected]

Sanofi forward-looking statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potentials of the product, or regarding the potential future revenues of the product. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in these forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond Sanofi’s control. , which could cause actual results and developments to differ materially from those expressed, implied or projected by the forward-looking information and statements. These risks and uncertainties include, among others, unexpected regulatory actions or delays, or government regulation generally, which could affect the availability or commercial potential of the product, the product’s failure to achieve commercial success, uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post-marketing, unexpected safety, quality or manufacturing issues, competition in general , risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that COVID-19 will have on us, our customers, suppliers, vendors and others business partners, and the financial condition of any of them, as well as on our employees and on the world economy in his outfit. Any material effect of COVID-19 on any of the above may also adversely impact us. This situation is changing rapidly and additional impacts may arise that we are not currently aware of and may exacerbate other previously identified risks. Risks and uncertainties also include uncertainties discussed or identified in public filings with the SEC and AMF by Sanofi, including those listed under “Risk Factors” and “Caution Regarding Forward-Looking Statements” in the Sanofi’s Annual Report on Form 20-F for the fiscal year ended December 31, 2021. Except as required by applicable law, Sanofi undertakes no obligation to update or revise any forward-looking information or statements.

  • CP Sanofi Global Health Unit 070422

Share.

Comments are closed.